|

Flt3/MerTK Inhibitor MRX-2843 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MRX 2843, MRX-2843, MRX2843

Pipeline

Phase 1: 1

Top Sponsors

  • Emory University1

Indications

  • Advanced Lung Non-Small Cell Carcinoma1
  • Stage IVB Lung Cancer AJCC v81
  • Stage IVA Lung Cancer AJCC v81
  • Stage IV Lung Cancer AJCC v81
  • Metastatic Lung Non-Small Cell Carcinoma1

Atlanta, Georgia1 trial

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Emory University Hospital/Winship Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.